We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+25.23%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.35B
AUM Growth
+$326M
Cap. Flow
+$191M
Cap. Flow %
14.16%
Top 10 Hldgs %
71.47%
Holding
42
New
4
Increased
13
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
LAB icon
Standard BioTools
LAB
+$147M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27.2M
3
VCYT icon
Veracyte
VCYT
+$20.9M
4
EXAS
Exact Sciences
EXAS
+$14.5M
5
RNAM
Avidity Biosciences
RNAM
+$14.2M

Top Sells

Rank Stock Value
1
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$31.9M
2
PLRX icon
Pliant Therapeutics
PLRX
+$9.52M
3
ILMN icon
Illumina
ILMN
+$8.96M
4
FATE icon
Fate Therapeutics
FATE
+$7.67M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$38.8B
$181M 13.46%
5,617,599
-97,176
-2% -$2.88M
LAB icon
2
Standard BioTools
LAB
$343M
$168M 12.47%
61,907,605
+60,707,605
+5,059% +$147M
BLFS icon
3
BioLife Solutions
BLFS
$1.56B
$162M 12.01%
8,707,165
– –
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.63B
$138M 10.29%
1,069,000
+62,500
+6% +$7.66M
RLAY icon
5
Relay Therapeutics
RLAY
$4.04B
$61.6M 4.58%
7,423,574
+35,631
+0.5% +$348K
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.1B
$53.5M 3.98%
358,000
+163,000
+84% +$27.2M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$53.2M 3.96%
2,084,841
+909,091
+77% +$14.2M
NTLA icon
8
Intellia Therapeutics
NTLA
$1.5B
$51.6M 3.83%
1,875,000
+425,000
+29% +$11.8M
GPCR icon
9
Structure Therapeutics
GPCR
$3.39B
$47.9M 3.56%
1,116,867
+25,000
+2% +$1.05M
EXAS
10
DELISTED
Exact Sciences
EXAS
$44.9M 3.34%
650,000
+230,000
+55% +$14.5M
VERV
11
DELISTED
Verve Therapeutics
VERV
$40.6M 3.02%
3,059,094
+50,000
+2% +$663K
TNYA icon
12
Tenaya Therapeutics
TNYA
$161M
$35.2M 2.62%
6,732,971
+351,594
+6% +$1.68M
ILMN icon
13
Illumina
ILMN
$30.2B
$34.1M 2.53%
254,944
-66,820
-21% -$8.96M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$31M 2.3%
326,378
– –
WGS icon
15
GeneDx Holdings
WGS
$1.98B
$28.6M 2.13%
3,136,411
+40,900
+1% +$246K
NGNE icon
16
Neurogene
NGNE
$657M
$26.7M 1.99%
524,616
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$26.7M 1.98%
1,300,000
– –
FDMT icon
18
4D Molecular Therapeutics
FDMT
$524M
$25.5M 1.89%
800,000
-233,811
-23% -$5.97M
BEAM icon
19
Beam Therapeutics
BEAM
$2.66B
$22.3M 1.66%
675,000
+147,000
+28% +$4.58M
VCYT icon
20
Veracyte
VCYT
$3.6B
$19M 1.41%
+857,904
New +$20.9M
PLRX icon
21
Pliant Therapeutics
PLRX
$64.4M
$14.9M 1.11%
1,000,000
-577,108
-37% -$9.52M
IPSC icon
22
Century Therapeutics
IPSC
$353M
$13.4M 1%
3,206,380
– –
TSVT
23
DELISTED
2seventy bio
TSVT
$10.7M 0.8%
2,000,000
+817,377
+69% +$3.84M
ABCL icon
24
AbCellera Biologics
ABCL
$1.78B
$10.7M 0.79%
2,360,129
– –
TNGX icon
25
Tango Therapeutics
TNGX
$4.43B
$9.44M 0.7%
1,188,349
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Casdin Capital held 42 positions worth $1.35B, up 32% from $1.02B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Casdin Capital deployed $191M of net new capital in Q1 2024, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Veracyte: 857,904 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Pliant Therapeutics, an estimated $9.52M trimmed.

  • Casdin Capital's largest Q1 2024 buy was Veracyte: 857,904 shares worth $19M.
  • Casdin Capital added most to Standard BioTools in Q1 2024, an estimated $147M increase.
  • Casdin Capital's biggest Q1 2024 reduction was Pliant Therapeutics, cutting an estimated $9.52M.
  • Casdin Capital fully exited SomaLogic, Inc. Class A Common Stock in Q1 2024, selling an estimated $31.9M.
  • Casdin Capital's ten largest holdings make up 71% of its $1.35B portfolio in Q1 2024.
  • Casdin Capital opened 4 new positions and closed 5 in Q1 2024.
  • Casdin Capital's portfolio value rose 32% quarter-over-quarter to $1.35B.

Based on Casdin Capital's 13F filing for Q1 2024, filed 15 May 2024.